Pregled bibliografske jedinice broj: 1269353
Serum calprotectin and CRP concentrations in COVID- 19 disease
Serum calprotectin and CRP concentrations in COVID- 19 disease // Clinical Chemistry and Laboratory Medicine (CCLM) ; 61, Issue s1 / Plebani, Mario (ur.).
Berlin : Boston: Walter de Gruyter, 2023. str. S626-S626 doi:10.1515/cclm-2023-7041 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1269353 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Serum calprotectin and CRP concentrations in COVID- 19 disease
Autori
Stančin, Nevenka ; Đerek, Lovorka ; Stolić, Jelena ; Butorac, Lucija ; Somborac Bačura, Anita
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Clinical Chemistry and Laboratory Medicine (CCLM) ; 61, Issue s1
/ Plebani, Mario - Berlin : Boston : Walter de Gruyter, 2023, S626-S626
Skup
IFCC-EFLM WorldLab EuroMedLab Roma 2023
Mjesto i datum
Rim, Italija, 21.05.2023. - 25.05.2023
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
calprotectin ; CRP ; COVID-19 ; serum ; biomarker
Sažetak
BACKGROUND-AIM The aim of this study was to evaluate the usefulness of serum calprotectin (sCAL) determination as well as the relationship between sCAL and CRP levels considering activity and severity of COVID-19. Both sCAL and CRP play important roles in the inflammatory response and could give different perspective on the course of the disease. METHODS Study included 143 subjects (70 female and 73 male) divided into four groups: patients that needed intensive care and mechanical ventilation (IC group, N=48), non- critical patients with oxygen treatment (RC group, N=22), patients in postcovid follow-up (PC, N=39) and healthy controls (HC, N=34). sCAL and CRP were determined on the AU5800 analyser (Beckman Coulter, Tokyo, Japan) Kruskal-Wallis and correlation analysis were used to test differences and connection between sCAL and CRP using MedCalc Statistical Software version 18.11.6 (MedCalc Software Bvba, Ostend, Belgium). RESULTS Median concentration with interquartile ranges were as follows: 6.27 [1.58-21.78] mg/L for sCAL and 100.4 [12.5-210.9] mg/L for CRP in IC group ; 5.04 [1.43-12.31] mg/L for sCAL and 69.3 [7.5-389.2] mg/L for CRP in RC group ; 1.68 [0.52-3.02] mg/L for sCAL and 2.2 [0.3-27.9] mg/L for CRP in PC group ; 0.68 [0.31 - 1.59] for sCAL and 1.3 [0.4- 16.4] for CRP in HC group. We found statistically significant differences for both sCAL and CRP between tested groups (P<0.001). Post-hoc analysis showed significant difference in CRP between hospitalized patients (IC and RC group) and non- hospitalized subjects (PC and HC group). sCAL showed similar statistics with one difference: sCAL was statistically higher in PC group than in the HC group (p<0.001) although these subjects were no longer in the acute phase of inflammation. sCAL showed a good positive correlation with CRP (r=0.64, P<0.001) CONCLUSIONS Our results showed that subjects with a severe course of the disease (IC and RC) had higher sCAL and CRP than subjects in postcovid or healthy group which defines sCAL as a useful biomarker that can predict the severity of COVID-19 disease. sCAL is also higher in postcovid group than in the healthy control group suggesting that the two tested markers do not follow the same dynamics in the acute inflammation that sCAL can be useful as a marker in the recovery period.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinička bolnica "Dubrava"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE